文献速递白血病造血干细胞移植与细胞治疗

B细胞活化因子受体在B淋巴母细胞白血病中的表达及靶向治疗意义

B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy.
PubMed 文献 · Br J Haematol · 2026-07-24

该研究采用多参数流式细胞术检测初诊及复发B-ALL新鲜样本中BAFF-R的表达。结果显示BAFF-R在多数病例中持续表达,且在CD19阴性复发及TP53异常的高危组中仍保留表达,支持其作为B-ALL免疫治疗靶点。

要点

  • BAFF-R在多数B-ALL病例中持续表达,水平低于成熟B细胞。
  • CD19阴性复发后BAFF-R表达仍保留,可作为替代靶点。
  • TP53异常在CD19阴性免疫逃逸病例中显著富集,但BAFF-R仍保留。

核心结论

  • BAFF-R是B-ALL中稳定的免疫治疗靶点,包括CD19阴性和TP53异常的复发疾病。

研究设计与样本

  • 采用多参数流式细胞术检测初诊和复发新鲜B-ALL样本的BAFF-R表达。

主要发现

  • BAFF-R在多数病例中持续表达,但水平低于成熟B细胞。
  • 多数CD19定向治疗后CD19阴性复发病例仍保留BAFF-R表达。
  • TP53异常在CD19阴性免疫逃逸疾病中显著富集(68.8% vs. 21.7%;p=0.0006;OR=7.9)。
  • BAFF-R表达在TP53异常的高危组中仍保留。

临床怎么用

  • BAFF-R可作为B-ALL特别是CD19阴性复发后的候选免疫治疗靶点。
  • 支持正在进行的BAFF-R定向CAR-T早期临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cluster of differrentiation 19 (CD19)-directed therapies have significantly improved outcomes in B-cell malignancies; however, relapse driven by antigen escape remains a major clinical challenge, underscoring the need for alternative therapeutic targets. The B-cell activating factor receptor (BAFF-R), a key regulator of B-cell survival, is highly expressed in mature B-cell neoplasms, but its relevance in B-lymphoblastic leukaemia (B-ALL) remains unclear. We assessed BAFF-R expression in diagnostic and relapsed fresh B-ALL samples using multi-parameter flow cytometry. BAFF-R was consistently expressed in most cases, albeit at lower levels than in mature B cells, and expression was retained in the majority of CD19-negative relapses following CD19-directed therapy. Notably, tumor protein p53 (TP53) alterations were significantly enriched in CD19-negative immune escape disease (68.8% vs. 21.7%; p = 0.0006; OR = 7.9), yet BAFF-R expression remained preserved in this high-risk group. These findings establish BAFF-R as a stable immunotherapeutic target in B-ALL, including in CD19-negative and TP53-altered relapsed disease, and underscore its relevance amid ongoing early-phase clinical trials of BAFF-R-directed chimeric antigen receptor (CAR) T-cell therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Tizro P, Aldoss I, Wang X, et al. B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy. Br J Haematol. 2026. PMID: 42496076. doi:10.1111/bjh.70708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。